A study on patients with NSCLC receiving nivolumab reported increased numbers of CD45RA+CCR7-CD8+ T cells in patients who achieved a partial response (PR) at baseline and after the second or third dose (18). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.